Rituximab (brand name Rituxan, among others) may be effective in treating patients with diffuse systemic sclerosis, according to a French retrospective study and literature review. Although there are several small-scale reports supporting rituximab as a treatment for systemic sclerosis (SSc) patients, no large-scale studies have been conducted. Researchers found it…
News
The presence of a specific scleroderma subtype and autoantibodies may be reliable factors to identify a distinct cancer risk in patients with scleroderma, according to a large prospective study. The study, “Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer,” was published in…
Treatment with iloprost using a portable pump is efficient, safe, and more convenient for the treatment of Raynaud’s phenomenon and digital ulcers in patients with scleroderma, a case report from Portugal shows. The pump helps patients…
The occurrence of blood clots in the veins of scleroderma patients is rare and does not change patients’ survival rates, a new Canadian study shows. Still, researchers see a need for improved understanding of venous thromboembolism (VTE) in these patients. The study, “Venous Thromboembolism in Systemic Sclerosis: Prevalence,…
News
Interstitial Lung Disease Associated with Greater Risk of Lung Cancer in Scleroderma, Study Reports
Having interstitial lung disease (ILD) is associated with a greater risk of lung cancer in scleroderma patients, according to Canadian researchers. Their findings also demonstrate that male sex and smoking are predictors for increased risk. Their study, “Interstitial lung disease is associated with an increased risk of lung…
A little-known government entity within the National Institutes of Health (NIH) is helping to lead U.S. efforts to speed up the development of therapies for some 7,000 rare diseases. The Office of Rare Diseases Research (ORDR), headquartered in Bethesda, Maryland, was established in 1993 within the NIH Office of the…
Therapeutic plasma exchange, which aims to treat systemic sclerosis (SSc) by clearing the blood of antibodies, cytokines and other factors that might promote disease progression, shows potential as a therapy, a review study reported. But a well-designed clinical trial, incorporating equipment and techniques that have come into use since therapeutic…
Increased levels of two proteins produced during acute inflammation can help predict pulmonary involvement in patients with diffuse systemic sclerosis, a study shows. Patients with diffuse systemic sclerosis who also have developed lung disease were found to have significantly higher levels of C-reactive protein (CRP) and serum amyloid A…
Changes in gene expression occur early in scleroderma patients with pulmonary arterial hypertension or interstitial lung disease, which means that a collection of biomarkers can be used to detect these lung conditions early, a study reports. The research dealt with what scientists call a biomarker panel for the conditions. The…
Almost a quarter of systemic sclerosis (SSc) patients with reduced gas exchange develop pulmonary hypertension (PH) within three years, according to a recent study that used right heart catheterization to measure pulmonary arterial pressures. Regular tests to assess PH, including right heart catheterization (RHC), might be useful in…
Recent Posts
- New anti-scarring pill shows encouraging safety in early trial
- No-touch light test may help in monitoring scleroderma skin changes
- Ultrasound technique may help detect muscle changes earlier in SSc
- Study ties acid reflux, bloating to fatigue in scleroderma
- Study links cancer in scleroderma to timing and autoantibodies
- Routine blood test may help flag lung disease risk in diffuse SSc, study says
- Nearly half with SSc consider facial cosmetic therapy, survey finds
- Inhaled therapy for Raynaud’s attacks put on FDA fast track
- Vitamin B3 may improve blood vessels in scleroderma-related Raynaud’s
- John Stamos to be honored for longtime support of scleroderma research